Borealis Biosciences
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $150M
Overview
A synthetic biology firm engineering live bacterial therapeutics to treat metabolic and inflammatory disorders.
MetabolicGastroenterology
Technology Platform
A synthetic biology platform for genetically engineering safe bacterial strains to function as live therapeutics that produce or degrade specific compounds in the human gut.
Funding History
1Total raised:$150M
Venture$150M
Opportunities
Potential to create a new class of durable, orally administered drugs for chronic conditions with high unmet need.
Risk Factors
Significant technical and regulatory risks associated with the predictable colonization, function, and long-term safety of engineered bacteria in humans.
Competitive Landscape
Competes in the emerging engineered live biotherapeutic product sector, where technological prowess in genetic circuit design and manufacturing are key differentiators.